Shares of Cryoport Inc. (CYRX) are down over 50% from their 52-week high of $14.21, recorded last May, to trade around $7.
The company is a global provider of temperature-controlled supply chain solutions for the life sciences sector, with a strong focus on regenerative medicine. It provides a full range of services and products to help biopharmaceutical companies, CDMOs, CROs, researchers, and drug developers manage the complex logistics of cell and gene therapies. By ensuring safe, reliable transport and storage, the company plays a key role in reducing risk and supporting the success of clinical trials and commercial launches worldwide. As of March 31, 2025, the company was supporting 711 clinical trials, including 79 in Phase 3, and 19 approved commercial therapies around the globe.
For comments and feedback: editorial@rttnews.com